Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

In a randomized trial of adults with obesity or overweight, Vanda Pharmaceuticals’ investigational NK-1 receptor antagonist ...

Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. On November 20, 2025, Inhibikase Therapeutics announced plans to advance IKT-001 ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade of ...

The mean systolic blood pressure (SBP) at baseline for Black and White patients not taking antihypertensive medication was ...

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 ...

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients ...

Vanda advances with strong Fanapt growth, late-stage catalysts, GLP-1 potential, higher investment and solid balance sheet ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Scientists have directly measured the minuscule electron sharing that makes precious-metal catalysts so effective. Their new technique, IET, reveals how molecules bind and react on metal surfaces with ...